CD Bioparticles launches comprehensive OMV-Based Bacterial Vaccines Development services for infectious disease and ...

Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.

How far can Robert Kennedy junior push state policies? West Virginia will provide an answer ...

A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...

The global autogenous vaccines market is growing steadily, valued at around US$ 312.4 million in 2026 and projected to reach ...

The global autogenous vaccines market is growing steadily, valued at around US$ 312.4 million in 2026 and projected to reach US$ 451.5 million by 2033, ...

Viral mimic systems and other tech platforms could enable local testing of vaccine candidates and antiviral therapies. This is important in the context of low-resourced health settings, Africa's focus ...

Biotechnology company Moderna (NASDAQ:MRNA) announced in Q4 CY2025, but sales fell by 29.8% year on year to $678 million. Its non-GAAP loss of $2.11 per share was 20.2% above analysts’ consensus ...

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

At issue with Moderna's mRNA flu shot is communication from CBER to Moderna suggesting that the company’s vaccine be compared ...

Automation and AI are revolutionizing the pharmaceutical industry, optimizing technical development and enabling faster, more reliable drug discovery processes.

The history of the hepatitis B vaccine has been marked by controversies, from the ‘Australia antigen’ to the ‘Pediatric Tuskegee.’ ...